pbh-20250630

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2025


OR


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the transition period from ____ to _____

Commission File Number: 001-32433

PRESTIGE CONSUMER HEALTHCARE INC.

(Exact Name of Registrant as Specified in Its Charter)


Delaware						20-1297589
(State or Other Jurisdiction of Incorporation or Organization)						(I.R.S. Employer Identification No.)

660 White Plains Road

Tarrytown, New York 10591

(Address of Principal Executive Offices) (Zip Code)

(914) 524-6800


(Registrant's Telephone Number, Including Area Code)

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)


Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.01 per share	PBH	New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

☒

Accelerated Filer

☐

Non-Accelerated Filer

☐

Smaller Reporting Company

☐

Emerging Growth Company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

As of August 1, 2025, there were 49,214,171 shares of common stock outstanding.

Prestige Consumer Healthcare Inc.

Form 10-Q

Index


PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements
	Condensed Consolidated Statements of Income and Comprehensive Income for the three months ended June 30, 2025 and 2024 (unaudited)	2
	Condensed Consolidated Balance Sheets as of June 30, 2025 and March 31, 2025 (unaudited)	3
	Condensed Consolidated Statements of Changes in Stockholders' Equity for the three months ended June 30, 2025 and 2024 (unaudited)	4
	Condensed Consolidated Statements of Cash Flows for the three months ended June 30, 2025 and 2024 (unaudited)	5
	Notes to Condensed Consolidated Financial Statements (unaudited)	6

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	19

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	28

Item 4.	Controls and Procedures	28

PART II.	OTHER INFORMATION

Item 1A.	Risk Factors	28

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	29

Item 5.	Other Information	29

Item 6.	Exhibits	30

	Signatures	31

TRADEMARKS AND TRADE NAMES

Trademarks and trade names used in this Quarterly Report on Form 10-Q are the property of Prestige Consumer Healthcare Inc. or its subsidiaries, as the case may be. We have italicized our trademarks and trade names when they appear in this Quarterly Report on Form 10-Q.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Prestige Consumer Healthcare Inc.

Condensed Consolidated Statements of Income and Comprehensive Income

(Unaudited)


	Three Months Ended June 30,
(In thousands, except per share data)		2025		2024
Revenues
Net sales		$	249,278	$	266,835
Other revenues		252		307
Total revenues		249,530		267,142

Cost of Sales
Cost of sales excluding depreciation		106,715		118,697
Cost of sales depreciation		2,484		2,423
Cost of sales		109,199		121,120
Gross profit		140,331		146,022

Operating Expenses
Advertising and marketing		34,937		39,365
General and administrative		28,456		28,910
Depreciation and amortization		5,182		5,701


Total operating expenses		68,575		73,976
Operating income		71,756		72,046

Other expense


Interest expense, net		10,203		13,137

Other (income) expense, net		(224)		496
Total other expense, net		9,979		13,633
Income before income taxes		61,777		58,413
Provision for income taxes		14,311		9,345




Net income		$	47,466	$	49,068

Earnings per share:
Basic		$	0.96	$	0.98
Diluted		$	0.95	$	0.98

Weighted average shares outstanding:
Basic		49,475		49,886
Diluted		49,833		50,267

Comprehensive income, net of tax:
Currency translation adjustments		5,404		3,160



Total other comprehensive income		5,404		3,160
Comprehensive income		$	52,870	$	52,228

See accompanying notes.

Prestige Consumer Healthcare Inc.

Condensed Consolidated Balance Sheets

(Unaudited)


(In thousands)	June 30, 2025		March 31, 2025

Assets
Current assets
Cash and cash equivalents	$	139,502	$	97,884
Accounts receivable, net of allowance of $14,065 and $16,314, respectively	168,405		194,293
Inventories	153,126		147,709

Prepaid expenses and other current assets	19,485		8,442

Total current assets	480,518		448,328

Property, plant and equipment, net	73,786		74,548
Operating lease right-of-use assets	26,918		28,238
Finance lease right-of-use assets, net	24,236		25,056
Goodwill	528,314		527,425
Intangible assets, net	2,294,829		2,295,350
Other long-term assets	3,024		3,273

Total Assets	$	3,431,625	$	3,402,218

Liabilities and Stockholders' Equity
Current liabilities

Accounts payable	$	22,206	$	18,925
Accrued interest payable	15,078		15,703
Operating lease liabilities, current portion	6,072		6,047
Finance lease liabilities, current portion	2,530		2,490
Other accrued liabilities	63,782		63,458

Total current liabilities	109,668		106,623




Long-term debt, net	992,749		992,357

Deferred income tax liabilities	426,947		419,594
Long-term operating lease liabilities, net of current portion	21,397		22,732
Long-term finance lease liabilities, net of current portion	19,976		20,624
Other long-term liabilities	5,406		5,391
Total Liabilities	1,576,143		1,567,321

Commitments and Contingencies — Note 14

Stockholders' Equity
Preferred stock - $0.01 par value
Authorized - 5,000 shares
Issued and outstanding - None	—		—
Common stock - $0.01 par value
Authorized - 250,000 shares
Issued - 56,171 shares at June 30, 2025 and 56,010 shares at March 31, 2025	561		560
Additional paid-in capital	600,238		593,402
Treasury stock, at cost - 6,960 shares at June 30, 2025 and 6,501 shares at March 31, 2025	(316,330)		(277,208)
Accumulated other comprehensive loss, net of tax	(32,255)		(37,659)
Retained earnings	1,603,268		1,555,802
Total Stockholders' Equity	1,855,482		1,834,897
Total Liabilities and Stockholders' Equity	$	3,431,625	$	3,402,218

See accompanying notes.

Prestige Consumer Healthcare Inc.

Condensed Consolidated Statements of Changes in Stockholders' Equity

(Unaudited)


	Three Months Ended June 30, 2025
	Common Stock			Additional Paid-in Capital		Treasury Stock			Accumulated Other Comprehensive Income (Loss)		Retained Earnings		Totals
(In thousands)	Shares	Par Value				Shares	Amount
Balances at March 31, 2025	56,010	$	560	$	593,402	6,501	$	(277,208)	$	(37,659)	$	1,555,802	$	1,834,897

Stock-based compensation	—	—		3,682		—	—		—		—		3,682
Exercise of stock options	53	—		3,155		—	—		—		—		3,155

Issuance of shares related to restricted stock	108	1		(1)		—	—		—		—		—
Treasury share repurchases	—	—		—		459	(39,122)		—		—		(39,122)




Net income	—	—		—		—	—		—		47,466		47,466


Comprehensive income	—	—		—		—	—		5,404		—		5,404

Balances at June 30, 2025	56,171	$	561	$	600,238	6,960	$	(316,330)	$	(32,255)	$	1,603,268	$	1,855,482


	Three Months Ended June 30, 2024
	Common Stock			Additional Paid-in Capital		Treasury Stock			Accumulated Other Comprehensive Income (Loss)		Retained Earnings		Totals
(In thousands)	Shares	Par Value				Shares	Amount
Balances at March 31, 2024	55,501	$	555	$	567,448	5,680	$	(219,621)	$	(34,495)	$	1,341,197	$	1,655,084


Stock-based compensation	—	—		3,425		—	—		—		—		3,425
Exercise of stock options	38

SEC Form 10-Q filed by Prestige Consumer Healthcare Inc.